LASIK Alternative Promises to Improve Vision Without Scalpel or Lasers

Researchers in the United States have reported reshaping rabbit corneas in isolated eyes by applying an electric potential, a method that the Argentine outlet El Cronista describes as an accidental discovery capable of correcting vision without surgery. The technique, highlighted by ScienceAlert as a LASIK alternative, reportedly alters the corneal surface without the need for a scalpel or laser. Coverage from ScienceDaily emphasizes that the approach could be safer and cheaper than existing laser‑based procedures. The experimental work was conducted on rabbit eyes kept outside the animal, according to UA.NEWS, and the results suggest a non‑invasive pathway to address astigmatism and myopia. El Cronista frames the finding as a potential end to operations for astigmatism and myopia, while the Korean business daily 매일경제 points out that millions of modern people currently visit LASIK or LASEK operating tables each year for vision correction.

UA.NEWS focuses on the technical detail that electric potential was the driving force behind corneal reshaping, and ScienceDaily stresses the promise of reduced risk and lower cost. ScienceAlert adds that the method could sidestep the need for incisions entirely, positioning it as a disruptive alternative to laser surgery. Laser‑assisted in‑situ keratomileusis (LASIK) and laser epithelial keratomileusis (LASEK) have become the dominant treatments for refractive errors, relying on precise laser ablation and, in some cases, a flap created with a microkeratome. The procedures, while effective for many, involve permanent alteration of corneal tissue, carry risks such as dry eye or flap complications, and require expensive equipment and specialist surgeons. The scale of their use, noted by 매일경제, underscores the market size that a non‑laser, non‑incisional technique would target.

Future coverage will need to track whether the electric‑potential method moves beyond isolated rabbit eyes into live‑animal models or early human trials. Regulatory bodies such as the U.S. Food and Drug Administration have not yet been mentioned, but any progression toward clinical use will likely involve trial registration and safety assessments. Observers should watch for announcements from the research team, peer‑reviewed publications, and potential commercial partnerships that could bring the technology to market.